JB
TCRX icon

Julian Baker’s TScan Therapeutics TCRX Stock Holding History

Julian Baker’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Hold
2,784,792
– – 0.01% 78
2026
Q1 		$2.81M Hold
2,784,792
– – 0.02% 79
2025
Q4 		$2.78M Hold
2,784,792
– – 0.02% 79
2025
Q3 		$5.07M Hold
2,784,792
– – 0.04% 73
2025
Q2 		$4.04M Hold
2,784,792
– – 0.04% 70
2025
Q1 		$3.84M Hold
2,784,792
– – 0.04% 64
2024
Q4 		$8.47M Hold
2,784,792
– – 0.09% 56
2024
Q3 		$13.9M Hold
2,784,792
– – 0.14% 47
2024
Q2 		$16.3M Hold
2,784,792
– – 0.21% 43
2024
Q1 		$22.1M Hold
2,784,792
– – 0.28% 40
2023
Q4 		$16.2M Hold
2,784,792
– – 0.18% 40
2023
Q3 		$7.13M Hold
2,784,792
– – 0.04% 57
2023
Q2 		$6.96M Hold
2,784,792
– – 0.04% 67
2023
Q1 		$5.85M Hold
2,784,792
– – 0.03% 69
2022
Q4 		$4.32M Hold
2,784,792
– – 0.03% 81
2022
Q3 		$8.49M Hold
2,784,792
– – 0.06% 65
2022
Q2 		$8.76M Buy
2,784,792
+1,359,792
+95% +$3.72M 0.05% 65
2022
Q1 		$3.99M Hold
1,425,000
– – 0.02% 92
2021
Q4 		$6.41M Hold
1,425,000
– – 0.03% 89
2021
Q3 		$11.9M Buy
+1,425,000
New +$13.2M 0.05% 74

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Julian Baker's TCRX Position: Q2 2026 in Review

Julian Baker held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 2,784,792 shares worth $2.73M. The position accounts for 0.01% of the portfolio, ranked #78.

Julian Baker first reported a position in TCRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $22.1M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Julian Baker held 2,784,792 shares of TScan Therapeutics worth $2.73M as of Q2 2026.
  • Julian Baker left its TScan Therapeutics share count unchanged in Q2 2026.
  • TScan Therapeutics made up 0.01% of Julian Baker's portfolio in Q2 2026, its #78 holding.
  • Julian Baker first reported a position in TScan Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Julian Baker's TScan Therapeutics position peaked at $22.1M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.